Gas phase conformational basicity of carvedilol fragment B, 2(S)-1-(ethylamonium)propane-2-ol:: An ab initio study on a protonophoretic of oxidative phosphorylation uncoupling

被引:6
作者
Almeida, DRP
Gasparro, DM
Pisterzi, LF
Torday, LL
Varro, A
Papp, JG
Penke, B
机构
[1] Univ Toronto, Lash Miller Labs, Dept Chem, Toronto, ON M5S 3H6, Canada
[2] Univ Szeged, Dept Pharmacol & Pharmacotherapy, H-6701 Szeged, Hungary
[3] Hungarian Acad Sci, Div Cardiovasc Pharmacol, H-6701 Szeged, Hungary
[4] Univ Szeged, H-6701 Szeged, Hungary
[5] Univ Szeged, Inst Med Chem, H-6720 Szeged, Hungary
[6] Univ Szeged, Prot Chem Res Grp, Hungarian Acad Sci, H-6720 Szeged, Hungary
来源
JOURNAL OF MOLECULAR STRUCTURE-THEOCHEM | 2003年 / 631卷
关键词
carvedilol; 2(S)-1-(ethylamonium)propane-2-ol; basicity; proton affinity; ab initio;
D O I
10.1016/S0166-1280(03)00258-6
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 [物理化学]; 081704 [应用化学];
摘要
Carvedilol is cardiovascular drug of proven efficacy. It is believed that carvedilol exerts cardio-protective effects by acting as a mild uncoupler of mitochondrial oxidative phosphorylation, thereby protecting mitochondria from oxidative stress and preserving proper bioenergetics and cardiac function. This uncoupling occurs via a proton-shuttling mechanism involving the amino group of carvedilol's side-chain. However, the molecular details of carvedilol's proton affinity have not yet been completely worked out, especially with regards to the attributes of molecular conformation. In the present study, the full conformational basicity of a fragment of carvedilol, 2(S)-1-(ethylamonium)propane-2-ol (Fragment B), is presented to illustrate the protonophoretic character of carvedilol. Full gas phase geometry optimizations were performed at the ab initio, RHF/3-21G, level of theory for the entire potential energy hypersurface (PEHS) of Fragment B. Subsequently, since deprotonation can occur via two different protons, a two-prong methodology was applied to calculate vertical and adiabatic energies of deprotonation. A total of 18 out of a possible 81 minima converged and the dominant characteristic in all protonated and deprotonated conformers was a gauche plus effect in the rotation about the C-OH bond at the Fragment B stereocentre. Optimized energies of deprotonation ranged from 245 to 262 kcal mol(-1) while protons involved in internal hydrogen bonding required an extra 6-8 kcal mol(-1) for deprotonation compared to protons that were oriented away from the backbone structure. The overall trend indicates that conformers devoid of significant stabilization interactions possessed lower energies of deprotonation; in other words, as the relative conformer energy increased, vertical and adiabatic energies of deprotonation tended to decrease. Thus, extrapolating to carvedilol and the proton transfer mechanism involved in oxidative phosphorylation uncoupling, events of deprotonation will favour molecular conformations with minimal intramolecular stabilization and with higher relative energies. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:251 / 270
页数:20
相关论文
共 21 条
[1]
Density functional molecular study on the full conformational space of the S-4-(2-hydroxypropoxy)carbazol fragment of carvedilol (1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanol) in vacuum and in different solvent media [J].
Almeida, DRP ;
Pisterzi, LF ;
Chass, GA ;
Torday, LL ;
Varro, A ;
Papp, JG ;
Csizmadia, MG .
JOURNAL OF PHYSICAL CHEMISTRY A, 2002, 106 (43) :10423-10436
[2]
Prospects in computational molecular medicine:: a millennial mega-project on peptide folding [J].
Berg, MA ;
Chasse, GA ;
Deretey, E ;
Füzéry, AK ;
Fung, BM ;
Fung, DYK ;
Henry-Riyad, H ;
Lin, AC ;
Mak, ML ;
Mantas, A ;
Patel, M ;
Repyakh, IV ;
Staikova, M ;
Salpietro, SJ ;
Tang, TH ;
Vank, JC ;
Perczel, A ;
Csonka, GI ;
Farkas, Ö ;
Torday, LL ;
Székely, Z ;
Csizmadia, IG .
JOURNAL OF MOLECULAR STRUCTURE-THEOCHEM, 2000, 500 :5-58
[3]
β-blockade therapy in chronic heart failure:: Diastolic function and mitral regurgitation improvement by carvedilol [J].
Capomolla, S ;
Febo, O ;
Gnemmi, M ;
Riccardi, G ;
Opasich, C ;
Caporotondi, A ;
Mortara, A ;
Pinna, G ;
Cobelli, F .
AMERICAN HEART JOURNAL, 2000, 139 (04) :596-608
[4]
CARLSON W, 1999, CARDIOVASC PHARM THE, V4, P205
[5]
Ferrari R, 1996, J CARDIOVASC PHARM, V28, pS1
[6]
Feuerstein G, 1998, Adv Pharmacol, V42, P611
[7]
Novel mechanisms in the treatment of heart failure: Inhibition of oxygen radicals and apoptosis by carvedilol [J].
Feuerstein, G ;
Yue, TL ;
Ma, XL ;
Ruffolo, RR .
PROGRESS IN CARDIOVASCULAR DISEASES, 1998, 41 (01) :17-24
[8]
A POTENT ANTIOXIDANT, SB209995, INHIBITS OXYGEN-RADICAL-MEDIATED LIPID-PEROXIDATION AND CYTOTOXICITY [J].
FEUERSTEIN, R ;
YUE, TL .
PHARMACOLOGY, 1994, 48 (06) :385-391
[9]
Frisch M.J., 2016, Gaussian 16 Revision C. 01. 2016, V16, P01
[10]
Heytler P G, 1979, Methods Enzymol, V55, P462